<DOC>
	<DOCNO>NCT02415127</DOCNO>
	<brief_summary>The purpose phase 3 randomize , multi-center , double-blind , placebo-controlled study evaluate efficacy safety ACTIMMUNE® ( interferon-γ 1b ) treatment Friedreich 's Ataxia ( FA ) evaluate pharmacokinetic ( PK ) characteristic ACTIMMUNE® FA patient .</brief_summary>
	<brief_title>Safety , Tolerability Efficacy ACTIMMUNE® Dose Escalation Friedreich 's Ataxia</brief_title>
	<detailed_description>Approximately 90 subject meet study eligibility criterion randomize 1:1 ratio receive SC dose either ACTIMMUNE® TIW match placebo TIW total 26 week ; study drug dose ( corresponding volume placebo ) plan escalated weekly basis first four week treatment ( 10 μg/m² 25 , 50 , 100 μg/m² equivalent volume placebo ) . The dose may reduce , interrupt , hold base tolerability .</detailed_description>
	<mesh_term>Ataxia</mesh_term>
	<mesh_term>Cerebellar Ataxia</mesh_term>
	<mesh_term>Friedreich Ataxia</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-gamma</mesh_term>
	<criteria>Written inform consent child assent , applicable . FA confirm genetic test two expanded guanineadenineadenine ( GAA ) repeat . FA functional stage &gt; 1 &lt; 5 ability walk 25 foot without assistive device . Male female subject age 10 25 year , inclusive . If female , subject pregnant lactating intend become pregnant study , within 30 day last dose study drug . Female subject childbearing potential must negative serum pregnancy test result Screening , negative urine pregnancy test result Baseline , agree use reliable method contraception throughout study 30 day last dose study drug . Any unstable illness investigator 's opinion precludes participation study . Use investigational product within 30 day prior randomization . A history substance abuse . Presence clinically significant cardiac disease ( determine investigator base electrocardiogram [ ECG ] echocardiogram result Screening ) . Specifically , ejection fraction &lt; 40 % prolonged QT interval ( &gt; 50 % cycle duration ) result exclusion . If investigator note clinically significant abnormality ECG echocardiogram , subject may eligible provided clearance cardiologist . History hypersensitivity IFNɣ E. coliderived product . Presence moderate severe renal disease ( estimate creatinine clearance &lt; 50 mL/min ) hepatic disease ( aspartate aminotransferase [ AST ] alanine aminotransferase [ ALT ] &gt; 2x upper limit normal ) evidence laboratory result Screening . Clinically significant abnormal white blood cell count , hemoglobin , platelet count evidence laboratory test result Screening .</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Interferon gamma</keyword>
</DOC>